How should impaired morning function in rheumatoid arthritis be treated?

Area of Science:

• Rheumatology
• Pharmacology
• Chronobiology

Background:

• Rheumatoid arthritis (RA) frequently causes debilitating morning joint stiffness and pain, impairing daily function.
• Current RA management for morning symptoms relies mainly on non-pharmacological methods, with limited success.
• A significant unmet need exists for pharmacological treatments specifically addressing morning dysfunction in RA patients.

Purpose of the Study:

• To investigate the potential of modified-release prednisone as a targeted treatment for morning symptoms in rheumatoid arthritis.
• To explore the underlying pathophysiology linking circadian rhythms, inflammation, and morning RA symptoms.

Main Methods:

• Review of clinical studies assessing pharmacological interventions for RA morning symptoms.
• Analysis of the role of interleukin-6 (IL-6) and endogenous cortisol in RA morning stiffness.
• Evaluation of chronotherapeutic approaches, specifically modified-release prednisone, for RA management.

Main Results:

• Suboptimal current treatments fail to adequately address morning RA symptoms, according to rheumatologist surveys.
• Elevated IL-6 levels during the night may contribute to RA morning stiffness.
• Modified-release prednisone, taken at bedtime, delivers prednisone optimally to suppress IL-6 and alleviate morning stiffness.

Conclusions:

• Understanding the circadian basis of RA symptoms is crucial for improving treatment efficacy.
• Modified-release prednisone offers a promising chronotherapeutic strategy for managing morning stiffness and pain in rheumatoid arthritis.
• Further research and clinical application of targeted chronotherapy may significantly enhance patient quality of life.